Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study, comparing consecutive high-risk allogeneic H...

Full description

Bibliographic Details
Main Authors: Léna Royston, Eva Royston, Stavroula Masouridi-Levrat, Nathalie Vernaz, Yves Chalandon, Christian Van Delden, Dionysios Neofytos
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Vaccines
Subjects:
letermovir
cytomegalovirus (CMV)
prophylaxis
allogeneic hematopoietic cell transplant recipients
recurrent CMV infection
Online Access:https://www.mdpi.com/2076-393X/9/4/372

Internet

https://www.mdpi.com/2076-393X/9/4/372

Similar Items